These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 12623838)

  • 1. Gammadelta T cells for immune therapy of patients with lymphoid malignancies.
    Wilhelm M; Kunzmann V; Eckstein S; Reimer P; Weissinger F; Ruediger T; Tony HP
    Blood; 2003 Jul; 102(1):200-6. PubMed ID: 12623838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.
    Dieli F; Vermijlen D; Fulfaro F; Caccamo N; Meraviglia S; Cicero G; Roberts A; Buccheri S; D'Asaro M; Gebbia N; Salerno A; Eberl M; Hayday AC
    Cancer Res; 2007 Aug; 67(15):7450-7. PubMed ID: 17671215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma.
    Kunzmann V; Bauer E; Feurle J; Weissinger F; Tony HP; Wilhelm M
    Blood; 2000 Jul; 96(2):384-92. PubMed ID: 10887096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma.
    Lang JM; Kaikobad MR; Wallace M; Staab MJ; Horvath DL; Wilding G; Liu G; Eickhoff JC; McNeel DG; Malkovsky M
    Cancer Immunol Immunother; 2011 Oct; 60(10):1447-60. PubMed ID: 21647691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo expansion and activation of γδ T cells as immunotherapy for refractory neuroblastoma: A phase 1 study.
    Pressey JG; Adams J; Harkins L; Kelly D; You Z; Lamb LS
    Medicine (Baltimore); 2016 Sep; 95(39):e4909. PubMed ID: 27684826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
    Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
    Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes.
    Nussbaumer O; Gruenbacher G; Gander H; Thurnher M
    Blood; 2011 Sep; 118(10):2743-51. PubMed ID: 21673342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-promoting versus tumor-antagonizing roles of γδ T cells in cancer immunotherapy: results from a prospective phase I/II trial.
    Kunzmann V; Smetak M; Kimmel B; Weigang-Koehler K; Goebeler M; Birkmann J; Becker J; Schmidt-Wolf IG; Einsele H; Wilhelm M
    J Immunother; 2012; 35(2):205-13. PubMed ID: 22306909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
    Meraviglia S; Eberl M; Vermijlen D; Todaro M; Buccheri S; Cicero G; La Mendola C; Guggino G; D'Asaro M; Orlando V; Scarpa F; Roberts A; Caccamo N; Stassi G; Dieli F; Hayday AC
    Clin Exp Immunol; 2010 Aug; 161(2):290-7. PubMed ID: 20491785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen.
    Miyagawa F; Tanaka Y; Yamashita S; Minato N
    J Immunol; 2001 May; 166(9):5508-14. PubMed ID: 11313389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
    Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
    Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells Costimulates pamidronate-activated gammadelta lymphocytes.
    Girlanda S; Fortis C; Belloni D; Ferrero E; Ticozzi P; Sciorati C; Tresoldi M; Vicari A; Spies T; Groh V; Caligaris-Cappio F; Ferrarini M
    Cancer Res; 2005 Aug; 65(16):7502-8. PubMed ID: 16103105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
    Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
    Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.
    Kobayashi H; Tanaka Y; Yagi J; Minato N; Tanabe K
    Cancer Immunol Immunother; 2011 Aug; 60(8):1075-84. PubMed ID: 21519826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion of human peripheral blood γδ T cells using zoledronate.
    Kondo M; Izumi T; Fujieda N; Kondo A; Morishita T; Matsushita H; Kakimi K
    J Vis Exp; 2011 Sep; (55):. PubMed ID: 21931292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirement of species-specific interactions for the activation of human gamma delta T cells by pamidronate.
    Kato Y; Tanaka Y; Tanaka H; Yamashita S; Minato N
    J Immunol; 2003 Apr; 170(7):3608-13. PubMed ID: 12646624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma.
    Saitoh A; Narita M; Watanabe N; Tochiki N; Satoh N; Takizawa J; Furukawa T; Toba K; Aizawa Y; Shinada S; Takahashi M
    Med Oncol; 2008; 25(2):137-47. PubMed ID: 18488155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens.
    Kato Y; Tanaka Y; Miyagawa F; Yamashita S; Minato N
    J Immunol; 2001 Nov; 167(9):5092-8. PubMed ID: 11673519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.